Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITM-31
- Development stage
- Unknown
- Lead developer
- ITM Isotope Technologies Munich
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intracavitary
01
Overview
ITM-31 (formerly known as LuCaFab) is a targeted radionuclide therapy (radioimmunotherapy) being developed for the treatment of malignant glioblastoma. It consists of a monoclonal antibody fragment (Fab), specifically the 6A10-Fab, which targets carbonic anhydrase XII (CA XII), conjugated to the beta-emitting radioisotope lutetium-177 (n.c.a. 177Lu, EndolucinBeta). CA XII is a protein highly expressed on the surface of glioblastoma cells but is largely absent in healthy brain tissue, enabling selective targeting of tumor cells. The therapy is administered via intracavitary injection directly into the resection cavity following standard surgical treatment, aiming to eliminate residual tumor cells and prevent or postpone recurrence. ITM-31 is being developed through a collaboration between Helmholtz Munich, University Hospital Münster, and ITM Isotope Technologies Munich SE.
- Other names
- Lu-177 labeled 6A10-Fab-fragmentsLu177 labeled 6A10-Fab-fragmentsLu 177 labeled 6A10-Fab-fragments177Lu-6A10-Fab
02
Targets
CA12 (Carbonic anhydrase XII)
Beyond the preview
Go deeper on ITM-31.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITM-31.